In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
Professor Warren Clements, interventional radiologist and head of the UAE service at The Alfred, said despite the proven safety and efficacy of the procedure – which was developed in the 1990s – it is simply not provided as an option to many women, something he urgently wants to change.
“Fibroids are highly prevalent in society and women need access to a range of different treatments so that they can choose what is the best for them,” Prof Clements said in an interview with Australian Health Journal.
“Every year, many women have a hysterectomy who would be suitable for a non-surgical alternative. UAE is an amazing non-surgical treatment and allows women to keep their uterus if they want to.”
The procedure is all done through a single pinhole incision, whereas a hysterectomy requires open surgery. It involves using low-dose x-rays and contrast dye to guide catheters through the arteries towards fibroids in the uterus. A medication is used to block the blood supply to the fibroids, which causes them to shrink. The procedure takes about half an hour, is done under ‘twilight’ sedation, and only requires one overnight recovery stay.
”Many women aren’t aware that this is a very minor procedure compared to hysterectomy,” Prof Clements said. “Women can resume normal activities the following day. The recovery is short, and most women can go back to work within a week. More than 90 per cent of women with heavy periods will have significant improvement in their symptoms after UAE.”
Professor Warren Clements, is also Honorary Researcher – Interventional Radiology, National Trauma Research Institute, Professor, Interventional Radiologist (IR) and the Head of Fluoroscopy in the Department of Radiology at Alfred Health. He is also a Fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR).
Credit: Alfred Health
-
Inaugural report into Australasian Paramedicine Workforce Survey report to aid workforce planning
In a milestone for paramedicine, the Australasian College of Paramedicine earlier this year released the first report of a landmark three-year study identifying and exploring trends that affect the Australasian paramedicine workforce.
The inaugural Australasian Paramedicine Workforce Survey report 2023-24 explores the demographic, career trajectory, work motivations and conditions for those working in clinical, management and educational capacities within the paramedicine workforce of Australia and Aotearoa New Zealand. -
Understanding extracellular vesicles in cancer therapy research
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
-
NSW Medical Device Commercialisation Training Program (MDCTP) Graduation 2019
Cicada Innovations with NSW Health this week hosted the graduation night for the 15 individuals that were part of the NSW Medical Device Commercialisation Training Program (MDCTP).
